Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma

Am J Clin Oncol. 1995 Oct;18(5):444-8. doi: 10.1097/00000421-199510000-00018.

Abstract

This article presents a young patient affected with non-Hodgkin lymphoma who developed acute myocardial infarction 7 days after treatment with epirubicin (90 mg/m2, day 1), cyclophosphamide (600 mg/m2, day 1), vincristine (2 mg, day 1), prednisolone (100 mg, days 1-5), and ondansetron (3 x 4 mg/day, days 1-2). Six months after the myocardial infarction the patient had no further cardiac complications after treatment with cylcophosphamide, vincristine, and ondansetron chemotherapy regimen. Epirubicin was considered to play an important role in the production of infarction, and the probable mechanisms of epirubicin-induced myocardial infarction are discussed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Epirubicin / administration & dosage
  • Epirubicin / adverse effects*
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Male
  • Myocardial Infarction / chemically induced*
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Epirubicin
  • Vincristine
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CEOP protocol 1